Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Multicenter, explorative, phase IIIb, open-label study to assess the efficacy and safety of
Ultrase® MT12, in the control of steatorrhea and clinical signs and symptoms of malabsorption
in CF children with pancreatic insufficiency (PI). This study is sponsored by Aptalis Pharma
(formerly Axcan).